NewsMV
Pacira BioSciences (PCSA) reported a net loss of $6.6 million for the six months ended June 30, 2026, in a filing that details the financial and operational risks associated with its ongoing merger with Vidya Therapeutics.
The company disclosed these figures alongside a comprehensive list of risk factors intended to inform investors of the challenges facing its clinical-stage development programs.
The filing states that the net loss for the same period in 2025 was $6.8 million. For the full years ended December 31, 2025 and 2024, Pacira reported net losses of $13.6 million and $11.9 million, respectively.
As of June 30, 2026, the company’s accumulated deficit stood at $107.4 million, up from $100.8 million as of December 31, 2025.
Keep reading